Although ibrutinib adds to the cost of treatment, its benefits over the long term justify the cost, investigators found. Adding ibrutinib (Imbruvica) to the R-CHOP regimen (rituximab, cyclophosphamide ...

Chemotherapy drugs can shrink tumors or kill stray cancer cells left behind after surgery or radiation. It’s also a systemic treatment, meaning its purpose is to kill cancer cells throughout your body ...

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...

Selection bias is one of the most common issues in designing trials. This is illustrated in the PYRAMID trial, which showed a 2-year PFS of 78% for patients with non-GCB DLBCL compared with a 2-year ...

Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with ...

CHICAGO -- Combining two targeted therapies with standard-of-care chemotherapy extended progression-free survival (PFS) in patients with newly diagnosed B-cell lymphomas, according to data from the ...

Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...

The proteasome inhibitor bortezomib was initially approved for the treatment of relapsed mantle-cell lymphoma. We investigated whether substituting bortezomib for vincristine in frontline therapy with ...

High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (APBSCT) has been widely used for patients with non-Hodgkin’s lymphoma (NHL). 1,2 One major obstacle to APBSCT ...